Scientific article
Open access

Les biomarqueurs du liquide céphalorachidien dans la maladie d'Alzheimer en pratique clinique courante

Published inRevue médicale suisse, vol. 12, no. 515, p. 791-794
Publication date2016

The cerebrospinal fluid levels of amyloid beta 1-42 (Aβ1-42), total tau and tau phosphorylated at threonine 181 (ptau181) are well established biomarkers of cerebral amyloid pathology and tau related neurodegeneration, two hallmarks of Alzheimer's disease. These biomarkers can help to improve diagnostic accuracy and consequent decisions on counseling, support, and therapy of patients with mild cognitive impairment and dementia. The use of biomarkers is part of the proposed new criteria of AD diagnosis. It may be particularly helpful in cases of atypical clinical presentation and uncertain diagnosis, and if an important benefit for the patient is expected. The ongoing development of new biomarkers based on less or non-invasive procedures will allow for a larger use of biomarkers to improve the diagnosis of cognitive impairment.

  • Alzheimer Disease/cerebrospinal fluid/diagnosis/therapy
  • Amyloid beta-Peptides/cerebrospinal fluid
  • Biomarkers/cerebrospinal fluid
  • Cognitive Therapy/methods
  • Diagnosis, Differential
  • Early Diagnosis
  • Humans
  • Predictive Value of Tests
  • Sensitivity and Specificity
  • tau Proteins/cerebrospinal fluid
Affiliation Not a UNIGE publication
Citation (ISO format)
MAGNIN, Eloi, POPP, Julius. Les biomarqueurs du liquide céphalorachidien dans la maladie d’Alzheimer en pratique clinique courante. In: Revue médicale suisse, 2016, vol. 12, n° 515, p. 791–794.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation06/08/2018 10:00:00 AM
First validation06/08/2018 10:00:00 AM
Update time03/15/2023 8:25:53 AM
Status update03/15/2023 8:25:53 AM
Last indexation01/17/2024 3:13:06 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack